Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07082816 · ClinicalTrials.gov registry record · Phase 3
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Alcon Research.
- Active
- Registry status
- Phase 3
- Development phase
- 489
- Enrollment target
- 20
- Study locations
NCT07082816: Active Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Alcon Research.
NCT07082816 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that is active but no longer recruiting, run by Alcon Research. The registered enrollment target is 489 participants, above the 269-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07082816, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, is active but no longer recruiting, sponsored by Alcon Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 489 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Primary Outcome
Intraocular pressure (IOP) will be measured with a Goldmann tonometer and recorded in millimeters mercury (mmHg). IOP will be calculated as the mean of two readings or the median of three readings at each timepoint.
Conditions Studied
Interventions
- DRUG Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
- DRUG Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
Study Locations (20)
Florida
- Central Florida Eye Specialists - DeLand
- Glaucoma Specialists of South Florida - Delray Beach
- East Coast Institute for Research, LLC - Jacksonville
- Central Florida Eye Associates - Lakeland
- The Eye Institute of West Florida - Largo
- Lee Shettle Eye - Largo
California
- Orange County Ophthalmology Medical Group - Garden Grove
- United Medical Research Institute - Inglewood
- Eye Research Foundation - Newport Beach
- North Bay Eye Associates - Petaluma
- Sacramento Eye Consultants - Sacramento
Georgia
- North Georgia Eye Associates - Gainesville
- Coastal Research Associates - Roswell
Alabama
- Trinity Research Group - Dothan
Arizona
- Eye Doctors of Arizona - Phoenix
Kansas
- Kannarr Eye Care LLC - Pittsburg
Massachusetts
- NorthEast Eye Research Associates, LLC - Westborough
Mississippi
- Coldwater Vision Research - Coldwater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What the registry record for NCT07082816 still lists
NCT07082816 is an interventional study that assigns participants to a tested intervention. The registered 489 participants enrollment target is mid-sized for trials with a published cap, above the 269-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (82% higher).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution is the first listed.
NCT07082816 names 20 study sites across 10 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07082816 about?
NCT07082816 is a clinical study titled "Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction". This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
What is the current status of trial NCT07082816?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 489 participants. The study started on 2025-09-02. Estimated completion is 2026-05.
What conditions does trial NCT07082816 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT07082816?
The interventions under investigation include: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution (DRUG), Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT07082816?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07082816 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07082816's enrollment target sits among peer trials
489 12th of 54 higher than 43 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI